Gene polymorphisms contributing to hypertension in immunoglobulin A nephropathy

Clinical and Experimental Nephrology

Volumn 16, Issue 2, 2012, Pages 250-258

  Shinzawa, Maki ^a   Yamamoto, Ryohei ^a   Nagasawa, Yasuyuki ^a   Shoji, Tatsuya ^b   Obi, Yoshitsugu ^a   Namba, Tomoko ^a   Kitamura, Harumi ^a   Kaneko, Tetsuya ^b   Okada, Noriyuki ^b   Iwatani, Hirotsugu ^a   Yamauchi, Atsushi ^b   Tsubakihara, Yoshiharu ^c   Imai, Enyu ^a   Isaka, Yoshitaka ^a   Rakugi, Hiromi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

ACE; Candidate genes approach; CD14; Hypertension; IgA nephropathy; Polymorphism; SNP

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG USE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLOMERULONEPHRITIS, IGA; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; YOUNG ADULT;

EID: 84863716529     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0553-7     Document Type: Article

References (40)

1. Barsoum R. Chronic kidney disease in the developing world. N Engl J Med. 2006;354(10):997-9.
2. System. USRD. USRDS 2008 annual data report: Atlas of endstage renal disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases, 2008; 2009.
3. Wiwanitkit V. Angiotensin-converting enzyme gene polymorphism is correlated to the progression of disease in patients with IgA nephropathy: A meta-Analysis. Ren Fail. 2006;28(8):697-9.
4. Koomans H, Roos J, Boer P, Geyskes G, Mees E. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension. 1982; 4(2):190-7.
5. Farmer C, Goldsmith D, Cox J, Dallyn P, Kingswood J, Sharpstone P. An investigation of the effect of advancing uraemia, renal replacement therapy and renal transplantation on blood pressure diurnal variability. Nephrol Dial Transplant. 1997; 12(11):2301-7.
6. Hering D, Zdrojewski Z, Król E, Kara T, Kucharska W, Somers V, et al. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J Hypertens. 2007;25(1):157-61.
7. Schiffrin EL, LipmanML,Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85-97.
8. Hausberg M, Grassi G. Mechanisms of sympathetic overactivity in patients with chronic renal failure: A role for chemoreflex activation? J Hypertens. 2007;25(1):47.
9. Chanda R, Fenves A. Hypertension in patients with chronic kidney disease. Curr Hypertens Rep. 2009;11(5):329-36.
10. Wright J, Hutchison A. Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag. 2009;5:713-22.
11. Burt V, Whelton P, Roccella E, Brown C, Cutler J, Higgins M, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25(3):305-13.
12. Kearney P, Whelton M, Reynolds K, Muntner P, Whelton P, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365(9455):217- 23.
13. Kosugi T, Nakagawa T, Kamath D, Johnson R. Uric acid and hypertension: An age-related relationship? J Hum Hypertens. 2009;23(2):75-6.
14. Yatsu K, Mizuki N, Hirawa N, Oka A, Itoh N, Yamane T, et al. High-resolution mapping for essential hypertension using microsatellite markers. Hypertension. 2007;49(3):446-52.
15. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997; 29(4):526-32.
16. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36(2):227-37.
17. Yamamoto R, Nagasawa Y, Shoji T, Iwatani H, Hamano T, Kawada N, et al. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis. 2010;56(2):313-24.
18. Yamamoto R, Nagasawa Y, Shoji T, Inoue K, Uehata T, Kaneko T, et al. A candidate gene approach to genetic prognostic factors of IgA nephropathy-A result of Polymorphism REsearch to DIstinguish genetic factors Contributing To progression of IgA Nephropathy (PREDICT-IgAN). Nephrol Dial Transplant. 2009;24(12):3686-94.
19. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982-92.
20. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002;347(24): 1916-23.
21. Walton K, Hsieh X, Gharavi N, Wang S, Wang G, Yeh M, et al. Receptors involved in the oxidized 1-palmitoyl-2-Arachidonoyl-snglycero- 3-phosphorylcholine-mediated synthesis of interleukin-8: A role for Toll-like receptor 4 and a glycosylphosphatidylinositolanchored protein. J Biol Chem. 2003;278(32):29661-6.
22. Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest. 1999;115(3):829-35.
23. Michel O, Kips J, Duchateau J, Vertongen F, Robert L, Collet H, et al. Severity of asthma is related to endotoxin in house dust. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1641-6.
24. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol. 1999;34(7): 1975-81.
25. Raunio T, Knuuttila M, Karttunen R, Vainio O, Tervonen T. Serum sCD14, polymorphism of CD14(-260) and periodontal infection. Oral Dis. 2009;15(7):484-9.
26. Amar J, Ruidavets JB, Bal Dit Sollier C, Bongard V, Boccalon H, Chamontin B, et al. Soluble CD14 and aortic stiffness in a population- based study. J Hypertens. 2003;21(10):1869-77.
27. Pacheco E, Fonseca C, Montes C, Zabaleta J, Garca LF, Arias MA. CD14 gene promoter polymorphism in different clinical forms of tuberculosis. FEMS Immunol Med Microbiol. 2004; 40(3):207-13.
28. Lin J, Yao YM, Yu Y, Chai JK, Huang ZH, Dong N, et al. Effects of CD14-159 C/T polymorphism on CD14 expression and the balance between proinflammatory and anti-inflammatory cytokines in whole blood culture. Shock. 2007;28(2):148-53.
29. Zee RY, Bates D, Ridker PM. A prospective evaluation of the CD14 and CD18 gene polymorphisms and risk of stroke. Stroke. 2002;33(4):892-5.
30. Risley P, Jerrard-Dunne P, Sitzer M, Buehler A, von Kegler S, Markus HS. Promoter polymorphism in the endotoxin receptor (CD14) is associated with increased carotid atherosclerosis only in smokers: the Carotid Atherosclerosis Progression Study (CAPS). Stroke. 2003;34(3):600-4.
31. Staessen J, Wang J, Ginocchio G, Petrov V, Saavedra A, Soubrier F, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens. 1997;15(12):1579.
32. Shinoda H, Nishimoto K, Mochizuki T. Screening examination of Trichophyton tonsurans among Judo practitioners at the All Japan Inter High School Championships, Saga 2007. Nippon Ishinkin Gakkai Zasshi. 2008;49(4):305-9.
33. Xie Y, Chen X, Nishi S, Narita I, Gejyo F. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int. 2004;65(4):1135-44.
34. Iio K, Nagasawa Y, Iwatani H, Yamamoto R, Horii A, Okuzaki D, et al. Microarray analysis of tonsils in immunoglobulin A nephropathy patients. Biochem Biophys Res Commun. 2010; 393(4):565-70.
35. Suzuki S, Nakatomi Y, Sato H, Tsukada H, Arakawa M. Haemophilus parainfluenzae antigen and antibody in renal biopsy samples and serum of patients with IgA nephropathy. Lancet. 1994;343(8888):12-6.
36. Suzuki S, Fujieda S, Sunaga H, Sugimoto H, Yamamoto C, Kimura H, et al. Immune response of tonsillar lymphocytes to Haemophilus parainfluenzae in patients with IgA nephropathy. Clin Exp Immunol. 2000;119(2):328-32.
37. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005; 16(7):2088-97.
38. Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 2006;69(11):1939-44.
39. Port FK, Eknoyan G. The Dialysis Outcomes and Practice Patterns Study (DOPPS) and the Kidney Disease Outcomes Quality Initiative (K/DOQI): A cooperative initiative to improve outcomes for hemodialysis patients worldwide. Am J Kidney Dis. 2004;44(5 Suppl 2):1-6.
40. Isnard Bagnis C, Deray G, Baumelou A, Le Quintrec M, Vanherweghem JL. Herbs and the kidney. Am J Kidney Dis. 2004;44(1):1-11.